



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



WNK-IN-11 Item No. 29676

CAS Registry No.: 2123489-30-3
Formal Name: [5-chloro-2-[2-(methylamino)-4-thiazolyl]-4-pyridinyl]
[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-methanone
MF: C₂₁H₂₁Cl₂N₅OS
FW: 462.4
Purity: ≥98%
UV/Vis.: λ_{max}: 221, 259, 325 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

WNK-IN-11 is supplied as a crystalline solid. A stock solution may be made by dissolving the WNK-IN-11 in the solvent of choice, which should be purged with an inert gas. WNK-IN-11 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of WNK-IN-11 in these solvents is approximately 3, 25, and 30 mg/ml, respectively.

WNK-IN-11 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, WNK-IN-11 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. WNK-IN-11 has a solubility of approximately 0.1 mg/ml in a 1:10 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

WNK-IN-11 is an allosteric inhibitor of lysine-deficient protein kinase 1 (WNK1; IC₅₀ = 4 nM).¹ It is 57- and 1,000-fold selective for WNK1 over WNK2 and WNK4, respectively, as well as a panel of 400 kinases at 10 μM. It inhibits WNK1-mediated phosphorylation of the transcription factor OSR1 in HEK293 cells (EC₅₀ = 0.352 μM).

Reference

1. Yamada, K., Levell, J., Yoon, T.K., *et al.* Optimization of allosteric with-no-lysine (WNK) kinase inhibitors and efficacy in rodent hypertension models. *J. Med. Chem.* **60**(16), 7099-7107 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/02/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM